Portage Biotech, NCI, Stimunity enter cooperative R&D agreement to develop STING agonists and anti-RAGE agents for cancer vaccines

Surviving cancer is often not a patient’s most challenging battle

With advances in treatment and screening for earlier detection, oncologists have improved cancer survival rates dramatically. That is excellent news, but the surging number of survivors means it is increasingly important for providers to focus more diligently on what patients need to thrive after treatment.

A farewell post by an unidentified NCI employee triggers an accusation of “undermining the Trump administration”

In the morning of May 28, presumably before turning off the lights and closing the office door, someone at the now defunct NCI Office of Communications and Public Liaision decided to post a farewell message to the cancer community. The message, posted on multiple social media accounts, read: We’re taking a pause here - but...

KU Cancer Center breaks ground for new complex

The University of Kansas Cancer Center broke ground on the future site of a new complex on May 22 that will bring research and patient care into one area for the first time in KU Cancer Center’s history.

May 30, 2025

Vol.51 No.21

Cancer Policy

The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo

On May 21, staff members of NCI’s dissolved Office of Communications and Public Liaison and friends gathered at the house of Peter Garrett and Ken Crerar.

May 23, 2025

Vol.51 No.20

Cancer Policy

NCI Cancer Information Highlights bulletin cut due to RIFs

NCI’s Cancer Information Highlights bulletin, a section of NCI’s Weekly Digest Bulletin that informs readers of research updates related to cancer causes, prevention, screening, treatment, and coping, will no longer be published due to restructuring and reductions in force at HHS.

May 23, 2025

Vol.51 No.20

Cancer Policy

Prasad’s stricter FDA policy for COVID-19 vaccines could limit future access

FDA—under the leadership of cyber-iconoclast and new director of the agency’s Center for Biologics Evaluation and Research, Vinay Prasad—is taking a new approach to COVID-19 vaccines.

May 23, 2025

Vol.51 No.20

By Claire Marie Porter